NCT03627065 - A Study of INCB050465 in Primary Sjögren's Syndrome | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2019

Primary Completion Date

December 7, 2019

Study Completion Date

January 2, 2020

Conditions

Primary Sjögren's Syndrome

Interventions

DRUG

Parsaclisib

Parsaclisib administered orally once daily at the protocol-defined dose.

Trial Locations (4)

The Center for Rheumatology and Bone Research, Wheaton

North Georgia Rheumatology Group, Lawrenceville

Advanced Pharma CR, Miami

Ramesh C. Gupta, MD, Memphis